Letter

Rosiglitazone and pioglitazone

Beware fractures

BMJ 2009; 339 doi: 10.1136/bmj.b3957 (Published 29 September 2009)
Cite this as: BMJ 2009;339:b3957

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Alok Dixit, assistant professor1,
  2. Pinki Pandey, assistant professor1
  1. 1M M Institute of Medical Science and Research, Mullana, Ambala, India 133203
  1. alkdxt{at}yahoo.co.in

    Juurlink and colleagues show that pioglitazone has fewer adverse cardiovascular outcomes than rosiglitazone, which may be a class effect.1 However, recent reports show that thiazolidinediones are associated with increased incidence of …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular